Please login to the form below

Not currently logged in
Email:
Password:

rosuvastatin calcium

This page shows the latest rosuvastatin calcium news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca settles with generic rivals in Crestor patent challenge

AstraZeneca settles with generic rivals in Crestor patent challenge

The company said it has entered into a settlement agreement with Actavis and Egis Pharmaceuticals over their plan to launch generic Crestor (rosuvastatin calcium), blocking competition for the product until May ... Actavis (formerly Watson Pharma) filed

Latest news

  • AstraZeneca wins stay on Crestor generics in US AstraZeneca wins stay on Crestor generics in US

    The court upheld an earlier district court ruling that the 314 patent on the active substance in Crestor - rosuvastatin calcium - is valid and enforceable, preventing generic drugmakers from launching copycat versions ... All the generic drugmakers with

  • AstraZeneca’s Evan Lippman takes US role at Merck KGaA

    Lippman joins EMD Serono from AstraZeneca (AZ) where he most recently served as executive director of the company's Crestor (rosuvastatin calcium) brand.

  • Crestor can't top Lipitor in head-to-head study

    A study comparing the effects of AstraZeneca's Crestor (rosuvastatin calcium) with Pfizer's Lipitor (atorvastatin calcium) in has found no difference between the statin drugs in preventing the progression of ... The SATURN trial was designed to look at

  • AZ's Q3 income up as sales stay flat

    The company said more than $350m of revenue was lost due to generic competition, cancelling out strong performances for statin Crestor (rosuvastatin calcium), antipsychotic Seroquel XR (quetiapine fumarate) and Symbicort

  • AstraZeneca partners with cooking website

    rosuvastatin calcium), which is approved to lower cholesterol in combination with diet and exercise.

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest appointments

  • Evan Lippman joins Aileron Therapeutics Evan Lippman joins Aileron Therapeutics

    Highlights of his career include a spell as executive director at AstraZeneca where he led on huge brands such as Crestor (rosuvastatin calcium) and Nexium (esomeprazole) and heading US business development

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics